Enrichment Strategies for Phase I Oncology Clinical Trials

Oncology Clinical TrialsStudy efficiency is critical in the competitive Phase I oncology environment where a large number of (NMEs) are all competing for the same medical resources.

There is a growing trend to evaluate predictive biomarkers in enriched patient populations in early phases of clinical trial. Novel biomarker-driven, adaptive clinical trial designs can facilitate rapid evaluation of drugs, help validate multiple predictive biomarkers, minimize exposure of patients to ineffective therapies, and potentially allow accelerated drug approval in molecularly defined populations. Continue reading